Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid
- Matthew R. Meyer
- , Kristopher M. Kirmess
- , Stephanie Eastwood
- , Traci L. Wente-Roth
- , Faith Irvin
- , Mary S. Holubasch
- , Venky Venkatesh
- , Ilana Fogelman
- , Mark Monane
- , Lucy Hanna
- , Gil D. Rabinovici
- , Barry A. Siegel
- , Rachel A. Whitmer
- , Charles Apgar
- , Randall J. Bateman
- , David M. Holtzman
- , Michael Irizarry
- , David Verbel
- , Pallavi Sachdev
- , Satoshi Ito
- Division of Nuclear Medicine
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- Department of Neurology
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- DBBS - Biomedical Informatics and Data Science
- DBBS - Neurosciences
- Hope Center for Neurological Disorders
- DBBS - Molecular Cell Biology
- Bursky Center for Human Immunology and Immunotherapy
- Center for Brain Immunology & Glia (BIG)
- Intellectual and Developmental Disabilities Research Center (IDDRC)
Research output: Contribution to journal › Article › peer-review
81
Link opens in a new tab
Scopus
citations